Incyte announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib, an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo. These data were presented in a late-breaking oral presentation at the 2023 American Academy of Dermatology Annual Meeting, held from March 17-21 in New Orleans. Results from the study demonstrate that treatment with oral povorcitinib was associated with substantial total body repigmentation in patients with extensive nonsegmental vitiligo, as measured by total Vitiligo Area Scoring Index scores. Specifically, the study met its primary endpoint and patients receiving povorcitinib experienced statistically superior improvements in T-VASI at Week 24 compared to placebo. Additionally, more patients who received povorcitinib achieved the key secondary endpoint of T-VASI50 at Week 24 and continued to improve during an open-label extension period through Week 36 of treatment, following dose adjustment.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on INCY:
- Incyte enters precision medicine strategic partnership with Caris Life Sciences
- Incyte to discontinue Phase 3 LIMBER-304 trial
- Incyte announces CHMP recommendation for approval of ruxolitinib cream
- Incyte announces 52-week results from povorcitinib trial
- Incyte price target raised to $100 from $95 at Cowen
Questions or Comments about the article? Write to editor@tipranks.com